Inventiva (IVA) Reports Q2 Loss of EUR0.60
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/16/2024
- Futures ease as bond yields stay elevated amid Middle East tensions
- Johnson & Johnson (JNJ) posts mixed results, narrows full-year guidance
- UnitedHealth to take up to $1.6 billion hit from Change Healthcare hack this year
- Asian shares slide on Fed rate cut rethink; China GDP in focus
- China Q1 GDP grows 5.3%, more than expected
- Trump Media & Technology Group (DJT) Files S-1
- Tesla (TSLA) Senior VP Drew Baglino Is Said To Leave The Company - Bloomberg
- General Motors (GM) Said to be Moving Detroit HQ to Dan Gilbert's Hudson Tower - Bloomberg
- The Israeli Air Force Has Completed Its Preparation For An Imminent Attack Against Iran - Reuters
- Biohaven Pharma (BHVN) presents update on degrader platform and summary of progress to date in Phase 1 single ascending dose study for BHV-1300
- After-hours movers: Tesla, Gildan Activewear, Macatawa Bank, and more
- Midday movers: Goldman Sachs and Meta Platforms rise; Apple and Tesla fall
- Nike, Alpine Immune Sciences rise premarket; CarMax, Robinhood and Regeneron fall
- After-hours movers: Alpine Immune Sciences, Costco, and more
- Midday movers: Delta, Taiwan Semiconductor rise; Hexcel falls
Inventiva reports 2021 first half financial results and provides a corporate update
September 20, 2021 4:10 PM EDTÂ
Cash and cash equivalents at 93.6 m as of June 30, 2021 compared to 105.7 m1 as of December 31, 2020 Initiation of the NATiV3 Phase III clinical study with lanifibranor in NASH R&D expenses of 19.1 m in H1 2021, up 52% compared to H1 2020, mainly driven by the preparation and initiation of the NATiV3 Phase III clinical trial Decision by AbbVie to initiate a Phase IIb clinical trial with cedirogant in patients with moderate to severe psoriasis following the demonstration of clinical proof of concept during AbbVies Phase Ib clinical trial ... More
